Tech Company Financing Transactions
K36 Therapeutics Funding Round
K36 Therapeutics, operating out of Cambridge, raised $30 million from Atlas Venture, F-Prime Capital and Eight Roads.
Transaction Overview
Company Name
Announced On
12/10/2021
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series A
Investors
Proceeds Purpose
The funds will be used to advance the company's lead candidate, KTX-1001, through its first clinical proof-of-concept studies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Main St.
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
K36's lead candidate is KTX-1001, a first-in-class, selective inhibitor of the histone methyltransferase (HMT) MMSET, which is overexpressed in up to 20% of multiple myeloma patients due to the t(4;14) translocation.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Terry Connolly
Vice President
Travis Quigley
VP - Manufacturing
Chad Lewis
VP - Operations
Bao-Van Linberg
Browse more venture capital transactions:
Prev: 12/10/2021: Fayre Labs venture capital transaction
Next: 12/10/2021: NextVivo venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs